Hemorrhagic Fever News and Research

RSS
Viral hemorrhagic fevers (VHFs) refer to a group of illnesses that are caused by several distinct families of viruses. In general, the term "viral hemorrhagic fever" is used to describe a severe multisystem syndrome (multisystem in that multiple organ systems in the body are affected). Characteristically, the overall vascular system is damaged, and the body's ability to regulate itself is impaired. These symptoms are often accompanied by hemorrhage (bleeding); however, the bleeding is itself rarely life-threatening. While some types of hemorrhagic fever viruses can cause relatively mild illnesses, many of these viruses cause severe, life-threatening disease.
NanoViricides signs research and development agreement with Dr. Eva Harris’s laboratory at UC Berkeley

NanoViricides signs research and development agreement with Dr. Eva Harris’s laboratory at UC Berkeley

Antibodies also contribute to severe dengue virus-induced disease, confirms La Jolla Institute for Allergy & Immunology

Antibodies also contribute to severe dengue virus-induced disease, confirms La Jolla Institute for Allergy & Immunology

NIAID awards Tulane University over $15M to develop Lassa fever vaccine and treatment

NIAID awards Tulane University over $15M to develop Lassa fever vaccine and treatment

NIH awards over $15M for Tulane University's collaborative effort to combat VHF

NIH awards over $15M for Tulane University's collaborative effort to combat VHF

Researchers identify antiviral small molecule that is effective against numerous viruses

Researchers identify antiviral small molecule that is effective against numerous viruses

Phase I clinical trial of XRX-001 for yellow fever initiated

Phase I clinical trial of XRX-001 for yellow fever initiated

NanoViricides outlines its technology and current drug programs at Biotech Showcase conference

NanoViricides outlines its technology and current drug programs at Biotech Showcase conference

TessArae's RM-Flu test granted FDA EUA

TessArae's RM-Flu test granted FDA EUA

NCKUH and NHRI sponsor virology lab in Vietnam Children’s Hospital

NCKUH and NHRI sponsor virology lab in Vietnam Children’s Hospital

Second-quarter fiscal 2010 results announced by Peregrine Pharmaceuticals

Second-quarter fiscal 2010 results announced by Peregrine Pharmaceuticals

Sanofi Pasteur expands dengue vaccine clinical program in Latin America

Sanofi Pasteur expands dengue vaccine clinical program in Latin America

Breakthrough findings may lead to new treatments for Ebola hemorrhagic fever

Breakthrough findings may lead to new treatments for Ebola hemorrhagic fever

NanoViricides announces filing of its quarterly report with the SEC

NanoViricides announces filing of its quarterly report with the SEC

Human movement is a key factor for dengue spread in Brazil

Human movement is a key factor for dengue spread in Brazil

TessArae introduces new integrated product solutions for testing human genetic disease

TessArae introduces new integrated product solutions for testing human genetic disease

USPTO awards Peregrine Pharmaceuticals patent for anti-viral uses of phosphatidylserine targeting antibodies

USPTO awards Peregrine Pharmaceuticals patent for anti-viral uses of phosphatidylserine targeting antibodies

Peregrine Pharmaceuticals establishes a new Anti-Viral Research Group

Peregrine Pharmaceuticals establishes a new Anti-Viral Research Group

Inviragen, SingVax merge their complementary vaccine pipelines

Inviragen, SingVax merge their complementary vaccine pipelines

AVI BioPharma receives $11.5M DTRA fund to develop AVI-7012 for treating Junin virus infection

AVI BioPharma receives $11.5M DTRA fund to develop AVI-7012 for treating Junin virus infection

Recent releases: PEPFAR in Zimbabwe; dengue in Thailand; blogs on improving U.S. foreign aid; examining allocations of health aid

Recent releases: PEPFAR in Zimbabwe; dengue in Thailand; blogs on improving U.S. foreign aid; examining allocations of health aid